Stifel Trust’s Pacira BioSciences PCRX Stock Holding History

Stifel Trust’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$165K	Hold	1,700	–	–	0.03%	192
2014 Q2	$157K	Buy	1,700 +25	+1%	+$1.9K	0.03%	195
2014 Q1	$118K	Sell	1,675 -250	-13%	-$17K	0.02%	209
2013 Q4	$111K	Buy	1,925 +425	+28%	+$22.3K	0.02%	205
2013 Q3	$73K	Hold	1,500	–	–	0.01%	241
2013 Q2	$44K	Buy	+1,500	New	+$43.4K	0.01%	258

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stifel Trust's PCRX Position: Q3 2014 in Review

Stifel Trust held its Pacira BioSciences (PCRX) position steady in Q3 2014 at 1,700 shares worth $165K. The position accounts for 0.03% of the portfolio, ranked #192.

Stifel Trust first reported a position in PCRX in Q2 2013 and has held it in 6 quarters since. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

Stifel Trust held 1,700 shares of Pacira BioSciences worth $165K as of Q3 2014.
Stifel Trust left its Pacira BioSciences share count unchanged in Q3 2014.
Pacira BioSciences made up 0.03% of Stifel Trust's portfolio in Q3 2014, its #192 holding.
Stifel Trust first reported a position in Pacira BioSciences in Q2 2013 and has held it in 6 quarters since.
208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on Stifel Trust's 13F filing for Q3 2014, filed 14 Nov 2014.